BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 27362268)

  • 1. FISHtrees 3.0: Tumor Phylogenetics Using a Ploidy Probe.
    Gertz EM; Chowdhury SA; Lee WJ; Wangsa D; Heselmeyer-Haddad K; Ried T; Schwartz R; Schäffer AA
    PLoS One; 2016; 11(6):e0158569. PubMed ID: 27362268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity yet conserved genomic imbalances and gain of MYC during progression.
    Heselmeyer-Haddad K; Berroa Garcia LY; Bradley A; Ortiz-Melendez C; Lee WJ; Christensen R; Prindiville SA; Calzone KA; Soballe PW; Hu Y; Chowdhury SA; Schwartz R; Schäffer AA; Ried T
    Am J Pathol; 2012 Nov; 181(5):1807-22. PubMed ID: 23062488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phylogenetic analysis of multiprobe fluorescence in situ hybridization data from tumor cell populations.
    Chowdhury SA; Shackney SE; Heselmeyer-Haddad K; Ried T; Schäffer AA; Schwartz R
    Bioinformatics; 2013 Jul; 29(13):i189-98. PubMed ID: 23812984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection.
    Hernandez L; Wilkerson PM; Lambros MB; Campion-Flora A; Rodrigues DN; Gauthier A; Cabral C; Pawar V; Mackay A; A'Hern R; Marchiò C; Palacios J; Natrajan R; Weigelt B; Reis-Filho JS
    J Pathol; 2012 May; 227(1):42-52. PubMed ID: 22252965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extensive ductal carcinoma In situ with small foci of invasive ductal carcinoma: evidence of genetic resemblance by CGH.
    Aubele M; Mattis A; Zitzelsberger H; Walch A; Kremer M; Welzl G; Höfler H; Werner M
    Int J Cancer; 2000 Jan; 85(1):82-6. PubMed ID: 10585588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
    Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L
    Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-Exome Sequencing Analysis of the Progression from Non-Low-Grade Ductal Carcinoma
    Pareja F; Brown DN; Lee JY; Da Cruz Paula A; Selenica P; Bi R; Geyer FC; Gazzo A; da Silva EM; Vahdatinia M; Stylianou AA; Ferrando L; Wen HY; Hicks JB; Weigelt B; Reis-Filho JS
    Clin Cancer Res; 2020 Jul; 26(14):3682-3693. PubMed ID: 32220886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
    Park K; Han S; Kim HJ; Kim J; Shin E
    Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic changes in intraductal breast cancer detected by comparative genomic hybridization.
    Kuukasjärvi T; Tanner M; Pennanen S; Karhu R; Kallioniemi OP; Isola J
    Am J Pathol; 1997 Apr; 150(4):1465-71. PubMed ID: 9095001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma.
    Johnson CE; Gorringe KL; Thompson ER; Opeskin K; Boyle SE; Wang Y; Hill P; Mann GB; Campbell IG
    Breast Cancer Res Treat; 2012 Jun; 133(3):889-98. PubMed ID: 22052326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
    Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
    Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer.
    Bergholtz H; Kumar S; Wärnberg F; Lüders T; Kristensen V; Sørlie T
    Cancer Rep (Hoboken); 2020 Jun; 3(3):e1248. PubMed ID: 32671987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 20q13.2 amplification in intraductal hyperplasia adjacent to in situ and invasive ductal carcinoma of the breast.
    Werner M; Mattis A; Aubele M; Cummings M; Zitzelsberger H; Hutzler P; Höfler H
    Virchows Arch; 1999 Nov; 435(5):469-72. PubMed ID: 10592049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic differences between pure ductal carcinoma in situ of the breast and that associated with invasive disease: a calibrated aCGH study.
    Iakovlev VV; Arneson NC; Wong V; Wang C; Leung S; Iakovleva G; Warren K; Pintilie M; Done SJ
    Clin Cancer Res; 2008 Jul; 14(14):4446-54. PubMed ID: 18628458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component.
    Zeng Y; Gao W; Chen X; Shen K
    Br J Cancer; 2021 Mar; 124(5):975-981. PubMed ID: 33335279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying a highly-aggressive DCIS subgroup by studying intra-individual DCIS heterogeneity among invasive breast cancer patients.
    Pape-Zambito D; Jiang Z; Wu H; Devarajan K; Slater CM; Cai KQ; Patchefsky A; Daly MB; Chen X
    PLoS One; 2014; 9(6):e100488. PubMed ID: 24978026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cis-acting super-enhancer lncRNAs as biomarkers to early-stage breast cancer.
    Ropri AS; DeVaux RS; Eng J; Chittur SV; Herschkowitz JI
    Breast Cancer Res; 2021 Oct; 23(1):101. PubMed ID: 34717732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
    Ottesen GL
    APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of heterozygosity analyses of asynchronous lesions of ductal carcinoma in situ and invasive ductal carcinoma of the human breast.
    Amari M; Moriya T; Ishida T; Harada Y; Ohnuki K; Takeda M; Sasano H; Horii A; Ohuchi N
    Jpn J Clin Oncol; 2003 Nov; 33(11):556-62. PubMed ID: 14711979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast carcinoma in sclerosing adenosis: a clinicopathological and immunophenotypical analysis on 206 lesions.
    Yu BH; Tang SX; Xu XL; Cheng YF; Bi R; Shui RH; Tu XY; Lu HF; Zhou XY; Yang WT
    J Clin Pathol; 2018 Jun; 71(6):546-553. PubMed ID: 29436376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.